课题基金 / 基金详情

14th Biennial Congress of the Anaerobes Society of the Americas

14th Biennial Congress of the Anaerobes Society of the Americas
第 14 届美洲厌氧菌协会双年度大会
批准号:
9543728
负责人:
JEANNE M MARRAZZO
金额:
$0.6万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-06-28 至 2019-05-31

项目摘要

项目成果

JEANNE M MARRAZZO的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 厌氧微生物,在没有氧气的情况下茁壮成长的细菌,是疾病的主要贡献者, 对人类健康至关重要。虽然艰难梭菌是一种严重的传染病威胁,也是导致 卫生保健相关的感染,我们越来越意识到,厌氧菌有助于以有益的方式, 人体微生物组的结构和功能。尽管区域性学会关注厌氧生物, 细菌科学存在于国外的选定地点(例如,英国、日本)、美洲厌氧生物学会 (ASA)是美国唯一一个致力于厌氧菌基础和临床科学的协会。此外,本发明还 阿萨长期以来一直拥有活跃国际成员,来自30多个国家的代表, 2016年双年度大会。阿萨及其两年一次的大会(成立于1992年)的长期目标是 通过对厌氧细菌及其环境的研究促进健康和科学进步。这 一项提案寻求NIH对ANAEROBE 2018的支持,这是阿萨的第14届两年一度的大会,将在 2018年7月9日至12日在内华达州拉斯维加斯举行。第十四届两年一次的大会的具体目标是:(1)促进 对厌氧菌的兴趣,并鼓励和促进来自所有学科的厌氧菌之间的交流, 包括医学、牙科、兽医、微生物学及基础科学等学科;(2)评估我们现时的 了解微生物群及其对健康疾病的贡献;(3)讨论争议, 梭菌属物种诱导疾病的研究进展和应对日益严重的抗菌药物问题 C.抗性艰难杆菌、拟杆菌属和其他厌氧菌;以及(4)探测新出现的 益生菌开发和临床应用中的作用机制、健康益处和监管问题 微生物群转移第14届两年一次的大会将通过多个国家的发言来实现这一目标。 20位国内外专家科学演讲人和多种演讲形式。组委会 委员会创建了一个计划,促进ANAEROBE参与者和与会者之间的多样性 2018.会议的一个房间,亲密的性质将鼓励一个衷心的,人对人, 一般不参加任何其他会议的科学家之间的跨学科交流 会场与NIH和NIAID的目标一致,阿萨第14届两年一度的大会提供了一个 独特的机会,汇集了世界领先的基础和临床研究人员在厌氧细菌 科学及其翻译,以促进对人类健康产生持久影响的研究。
英文摘要
Project Summary Anaerobes, bacteria that thrive in the absence of oxygen, are both major contributors to disease as well as critical to human health. While Clostridium difficile is a serious infectious disease threat and a leading cause of healthcare-associated infections, we are increasingly aware that anaerobes contribute in a beneficial way to the structure and function of the human microbiome. Although regional Societies focused on anaerobe bacterial science exist in select locales abroad (e.g., Britain, Japan), the Anaerobe Society of the Americas (ASA) is the only United States-based Society devoted to the basic and clinical science of anaerobes. Further, the ASA has long had an active international membership with representation from more than 30 countries at the 2016 Biennial Congress. The long-term goal of the ASA and its biennial congress (founded in 1992) is to promote health and advance science through the study of anaerobic bacteria and their environments. This proposal seeks NIH support for ANAEROBE 2018, the 14th Biennial Congress of the ASA, which will be hosted from July 9-12, 2018 in Las Vegas, NV. The specific aims of the 14th Biennial Congress are: (1) to stimulate interest in anaerobes and to encourage and facilitate interchange among anaerobists from all disciplines, including medical, dental, veterinary, microbiology and basic sciences fields of study; (2) to assess our current understanding of the microbiota and its contribution to health disease; (3) to discuss controversies and advances in disease induction by Clostridium species and grapple with the increasing problem of antimicrobial resistance in C. difficile, Bacteroides species, and other anaerobic bacteria; and (4) to probe emerging mechanisms of action, health benefits, and regulatory issues in probiotic development and clinical use of microbiota transfer. The 14th Biennial Congress will accomplish this goal through presentations by more than 20 domestic and international expert scientific speakers and a variety of presentation formats. The Organizing Committee has created a program that fosters diversity among the participants and attendees at ANAEROBE 2018. The one-room, intimate nature of the conference will encourage a hearty, person-to-person, interdisciplinary exchange between scientists who do not generally meet together in any other conference venue. Consistent with the goals of the NIH and NIAID, the 14th Biennial Congress of the ASA provides a unique opportunity to bring together the world’s leading basic and clinical investigators in anaerobe bacterial science and its translation toadvance studies with lasting impact on human health.!
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Sexually Transmitted Infections Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for Neisseria Gonorrhoeae
Sexually Transmitted Infections Clinical Trials Group
Sexually Transmitted Infections Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for Neisseria Gonorrhoeae
Sexually Transmitted Infections Clinical Trials Group
海外基金